





August 24-26, 2015 Philadelphia, USA

### Identification of the antimalarial artemisininnaphthoquine phosphate as effective therapeutic combination against Schistosoma haematobium

Samar N. Beshbishi<sup>1\*</sup>, Samia El Bardicy<sup>2</sup>, Menerva Tadros<sup>2</sup>, Magda Ayoub<sup>2</sup>, Amira Taman<sup>1</sup>


<sup>1</sup>Department of Medical Parasitology, Faculty of Medicine, Mansoura University, Egypt.

<sup>2</sup>Department of Medical Malacology, Theodor Bilharz Research Institute, Giza, Egypt.

## **BACKGROUND & OBJECTIVES**

- > Schistosomiasis is a worldwide public health challenge.
- > Schistosoma haematobium- and S. mansoni-endemic areas.
- > Praziquantel is the drug of choice.
- Efforts for testing existing drugs.
- Resistance with monotherapy.
- > Effective drug combination.





> The compound naphthoquine phosphate tablet (CO-ArNp).

> CO-ArNp significantly reduced worm burdens in S. mansoni-

infected mice

(El-Beshbishi *et al.*, 2013).



Contents lists available at SciVerse ScienceDirect

#### International Journal for Parasitology

journal homepage: www.elsevier.com/locate/ijpara



First insight into the effect of single oral dose therapy with artemisinin-naphthoquine phosphate combination in a mouse model of Schistosoma mansoni infection

Samar N. El-Beshbishi <sup>a,\*</sup>, Amira Taman <sup>a</sup>, Mohamed El-Malky <sup>a,b</sup>, Manar S. Azab <sup>a</sup>, Amira K. El-Hawary <sup>c</sup>, Dina A. El-Tantawy <sup>c</sup>

Potent in vitro effects of CO-ArNp against S. mansoni and its snail

host

(El-Beshbishi et al., 2015).



Contents lists available at ScienceDirect

#### Acta Tropica

journal homepage: www.elsevier.com/locate/actatropica



Spotlight on the *in vitro* effect of artemisinin-naphthoquine phosphate on *Schistosoma mansoni* and its snail host *Biomphalaria alexandrina* 




Samar N. El-Beshbishi a.e., Samia El Bardicyb, Menerva Tadrosb, Magda Ayoubb, Amira Tamana


- ☐ Examine CO-ArNp-similar *in vitro* efficacy on *S. haematobium*.
- ☐ The long term goal is to assess its potential use as broad-spectrum antischistosomal drug.

## **MATERIALS & METHODS**

### 1. Drugs

- CO-ArNp
- Praziquantel





#### 2. Animals and parasites

- Male golden hamsters
- Bulinus truncatus



### 3. In vitro schistosomicidal activity

- CO-ArNp at 1-40μg/ml
- PZQ at 10µg/ml

4

Medium without and medium with 0.8% DMSO




Inspect S, FEI Company, Holland









**Fig.1.** Dose- and time-response curves of adult *S. haematobium* exposed to CO-ArNp for 72 h.

**Table 1.** Motility scores of control and treated *S. haematobium* adult worms at different times post-incubation.

Groups	Percentage of worms in each motility score post-incubation										
	24 h			48 h			72 h				
	3	1.5	0	3	1.5	0	3	1.5	0		
Control	100			100			100				
PZQ		54.55	45.45			100			100		
CO-ArNp											
$1 \mu g/ml$		100			100			100			
$2  \mu g/ml$		100			100			100			
$4  \mu g/ml$		100			100			100			
$6  \mu g/ml$		100			100			100			
$8  \mu g/ml$		100			100			91.31	<b>8.69</b>		
$10~\mu g/ml$		100			100			66.66	33.33		
$20~\mu g/ml$		100			75	<b>25</b>			100		
$30~\mu g/ml$		100				100			100		
$40~\mu g/ml$		100				100			100		

Motility scores: 3, complete body movement; 1.5, partial body movement; 0, die

**Table 2.** *In vitro* effect of PZQ and CO-ArNp on the mortality of male & female S. haematobium worms under culture conditions.

Groups	Percentage of dead worms post-incubation										
	24 h		48 h		72 h						
	male	female	male	female	male	female					
PZQ	<mark>60</mark>	14.28	100	100	100	100					
CO-ArNp											
1 μg/ml	0	0	0	0	0	0					
$2  \mu g/ml$	0	0	0	0	0	0					
$4  \mu g/ml$	0	0	0	0	0	0					
6 μg/ml	0	0	0	0	0	0					
8 μg/ml	0	0	0	0	6.66	12.5					
$10 \ \mu g/ml$	0	0	0	0	25	50					
20 μg/ml	0	0	0	50	100	100					
30 μg/ml	0	0	100	100	100	100					
$40~\mu g/ml$	0	0	100	100	100	100					




Fig. 2. SEM of middle part of female *S.haematobium*, 48 h post-incubation.




Fig. 3. SEM of middle part of male *S. haematobium*, 48 h post-incubation.




Fig. 3. SEM of of male S. haematobium, 48 h post-incubation.

## **SUMMARY & CONCLUSION**

- ✓ Assessment of the anti-malarial; CO-ArNp on *S. haematobium*.
- ✓ The lethal effect of CO-ArNp on *S. haematobium*.
- ✓ A 100% mortality at 20  $\mu$ g/ml after 72h.
- ✓ A 100% mortality rate at 30  $\mu$ g/ml after 48h.
- ✓ SEM revealed marked tegumental alterations.
- ✓ CO-ArNp has important potential as a novel schistosomicidal.

# RECOMMENDATION

☐ Effects on other schistosomes and snail hosts.
☐ Possible mechanism/s of action.
☐ Studies in humans with current antimalarial dose.
☐ Assess its value to eradicate both parasitic diseases.
☐ Develop the most feasible & cost-effective strategies for the different endemic areas.

